TY  - JOUR
AU  - García-Donas, Jesus
AU  - Font, Albert
AU  - Pérez-Valderrama, Begoña
AU  - Virizuela, José Antonio
AU  - Climent, Miquel Ángel
AU  - Hernando-Polo, Susana
AU  - Arranz, José Ángel
AU  - Del Mar Llorente, Maria
AU  - Lainez, Nuria
AU  - Villa-Guzmán, José Carlos
AU  - Mellado, Begoña
AU  - González Del Alba, Aránzazu
AU  - Castellano, Daniel
AU  - Gallardo, Enrique
AU  - Anido, Urbano
AU  - García Del Muro, Xavier
AU  - Domènech, Montserrat
AU  - Puente, Javier
AU  - Morales-Barrera, Rafael
AU  - Pérez-Gracia, Jose Luis
AU  - Bellmunt, Joaquim
PY  - 2017
DO  - 10.1016/S1470-2045(17)30242-5
UR  - http://hdl.handle.net/10668/11067
T2  - The Lancet. Oncology
AB  - Maintenance therapy improves outcomes in various tumour types, but cumulative toxic effects limit the choice of drugs. We investigated whether maintenance therapy with vinflunine would delay disease progression in patients with advanced urothelial...
LA  - en
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Agents
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Asthenia
KW  - Carboplatin
KW  - Carcinoma, Transitional Cell
KW  - Cisplatin
KW  - Constipation
KW  - Deoxycytidine
KW  - Disease Progression
KW  - Disease-Free Survival
KW  - Fatigue
KW  - Female
KW  - Follow-Up Studies
KW  - Humans
KW  - Intention to Treat Analysis
KW  - Maintenance Chemotherapy
KW  - Male
KW  - Middle Aged
KW  - Neutropenia
KW  - Urologic Neoplasms
KW  - Vinblastine
KW  - Gemcitabine
TI  - Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial.
TY  - research article
VL  - 18
ER  -